Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Subsidiary Raising $5M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today announced that its Malaysian subsidiary has signed a purchase agreement with an investor for a $5 million private placement.

The investor, the Malaysian Technology Development Corporation, will purchase the subsidiary's Series C-1 redeemable convertible preference shares at a price of $1.55 per share. MTDC has the right to acquire up to $2.5 million of Series C-2 preference shares of the subsidiary at $2.32 per share for up to 36 months after the closing, which is expected this month.

The redeemable convertible preference shares will be converted into shares of WaferGen Biosystems common stock on a one-for-one basis within one year of issuance, WaferGen said in a statement. MTDC had previously invested in WaferGen Biosystems.

WaferGen said that it plans to use net proceeds from the financing for general corporate and working capital purposes, including broad commercialization of its SmartChip Real-Time PCR system launched in August.

On Tuesday, the Fremont, Calif.-based company disclosed in a filing with the US Securities and Exchange Commission a $2 million loan agreement with Oxford Finance Corp.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.